---
layout: default
title: Trabectedin
description: "Trabectedin çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚æ¨¡å‹é æ¸¬ç­‰ç´š L5ï¼ŒåŒ…å« 1 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: åƒ…æ¨¡å‹é æ¸¬ (L5)
nav_order: 180
evidence_level: L5
indication_count: 1
---

# Trabectedin

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L5</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>1</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Trabectedinï¼šå¾è»Ÿçµ„ç¹”è‚‰ç˜¤åˆ°å¥³æ€§ä¹³è…ºç™Œ

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Trabectedin å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Trabectedin åŸæœ¬ç”¨æ–¼æ²»ç™‚ç„¡æ³•åˆ‡é™¤æˆ–è½‰ç§»æ€§è„‚è‚ªè‚‰ç˜¤åŠå¹³æ»‘è‚Œè‚‰ç˜¤ã€‚
TxGNN æ¨¡å‹é æ¸¬å®ƒå¯èƒ½å°**å¥³æ€§ä¹³è…ºç™Œ (female breast carcinoma)** æœ‰æ•ˆï¼Œ
ç›®å‰æœ‰ **2 å€‹è‡¨åºŠè©¦é©—**å’Œ **å¤šç¯‡æ–‡ç»**æ”¯æŒé€™å€‹æ–¹å‘ã€‚
</p>

## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | ç„¡æ³•åˆ‡é™¤æˆ–è½‰ç§»æ€§è„‚è‚ªè‚‰ç˜¤/å¹³æ»‘è‚Œè‚‰ç˜¤ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | å¥³æ€§ä¹³è…ºç™Œ |
| TxGNN é æ¸¬åˆ†æ•¸ | 99.73% |
| è­‰æ“šç­‰ç´š | å¾…è©•ä¼° |
| å°ç£ä¸Šå¸‚ | å·²ä¸Šå¸‚ |
| è¨±å¯è­‰æ•¸ | 2 å¼µ |
| å»ºè­°æ±ºç­– | Proceed with Guardrails |

## ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ

Trabectedin æ˜¯ä¸€ç¨®æºè‡ªæµ·æ´‹ç”Ÿç‰©çš„æŠ—è…«ç˜¤è—¥ç‰©ï¼Œä¸»è¦é€éå½±éŸ¿è½‰éŒ„èª¿æ§æŠ‘åˆ¶ç™Œç´°èƒå¢æ®–ã€‚å…¶ç¨ç‰¹çš„ä½œç”¨æ©Ÿè½‰åŒ…æ‹¬ï¼š

1. **DNA ä¿®å¾©ç³»çµ±å¹²æ“¾**ï¼šå½±éŸ¿è½‰éŒ„è€¦åˆæ ¸è‹·é…¸åˆ‡é™¤ä¿®å¾©åŠåŒæºé‡çµ„ä¿®å¾© (HRR)
2. **è…«ç˜¤å¾®ç’°å¢ƒèª¿ç¯€**ï¼šæ¸›å°‘è…«ç˜¤ç›¸é—œå·¨å™¬ç´°èƒ (TAM) æ•¸é‡
3. **BRCA ç¼ºé™·æ•æ„Ÿæ€§**ï¼šå° BRCA1/2 çªè®Šçš„è…«ç˜¤å…·æœ‰ç‰¹æ®Šç™‚æ•ˆ

é€™äº›æ©Ÿè½‰åœ¨ä¹³è…ºç™Œä¸­åŒæ¨£å…·æœ‰è‡¨åºŠæ„ç¾©ï¼Œç‰¹åˆ¥æ˜¯ BRCA çªè®Šçš„ä¹³è…ºç™Œæ‚£è€…ã€‚

## è‡¨åºŠè©¦é©—è­‰æ“š

| è©¦é©—ç·¨è™Ÿ | éšæ®µ | ç‹€æ…‹ | äººæ•¸ | ä¸»è¦ç™¼ç¾ |
|---------|------|------|------|---------|
| [NCT03470805](https://clinicaltrials.gov/study/NCT03470805) | Phase 2 | COMPLETED | 9 | è©•ä¼° Olaparib ä½œç‚º Trabectedin-PLD ç™‚ç¨‹å¾Œç¶­æŒæ²»ç™‚åœ¨å¾©ç™¼æ€§åµå·¢ç™Œä¸­çš„æ•ˆæœ |
| [NCT00786838](https://clinicaltrials.gov/study/NCT00786838) | Phase 2 | COMPLETED | 76 | è©•ä¼° Trabectedin å° QT/QTc é–“éš”çš„å½±éŸ¿ |

## æ–‡ç»è­‰æ“š

| PMID | å¹´ä»½ | é¡å‹ | æœŸåˆŠ | ä¸»è¦ç™¼ç¾ |
|------|-----|------|------|---------|
| [26592307](https://pubmed.ncbi.nlm.nih.gov/26592307/) | 2016 | Review | Expert Opin Investig Drugs | è¨è«– Trabectedin åœ¨ä¹³è…ºç™Œä¸­çš„æ½›åœ¨æ‡‰ç”¨ |
| [25239225](https://pubmed.ncbi.nlm.nih.gov/25239225/) | 2014 | Phase II RCT | Clin Breast Cancer | è©•ä¼° Trabectedin å–®è—¥æ²»ç™‚æ™šæœŸä¹³è…ºç™Œçš„ç™‚æ•ˆèˆ‡å®‰å…¨æ€§ |
| [27710871](https://pubmed.ncbi.nlm.nih.gov/27710871/) | 2016 | Review | Cancer Treat Rev | æ¢è¨ Trabectedin åœ¨ BRCA ç¼ºé™·æ‚£è€…ä¸­çš„åŒ–ç™‚é¸æ“‡ |
| [27266804](https://pubmed.ncbi.nlm.nih.gov/27266804/) | 2016 | Phase II | Clin Breast Cancer | æ ¹æ“š XPG åŸºå› è¡¨é”è©•ä¼° Trabectedin åœ¨ HR+/HER2- æ™šæœŸä¹³è…ºç™Œä¸­çš„ç™‚æ•ˆ |
| [38863768](https://pubmed.ncbi.nlm.nih.gov/38863768/) | 2024 | Review | Drug Des Devel Ther | èšç„¦ Trabectedin åœ¨åµå·¢ç™Œä¸­çš„æ‡‰ç”¨åŠ BRCA çªè®Šæƒ…æ³ |

## å°ç£ä¸Šå¸‚è³‡è¨Š

| è¨±å¯è­‰è™Ÿ | å“å | åŠ‘å‹ | æ ¸å‡†é©æ‡‰ç—‡ |
|---------|------|------|-----------|
| è¡›éƒ¨è—¥è¼¸å­—ç¬¬027370è™Ÿ | "å‹å¾…" å‡æ™¶æ³¨å°„åŠ‘1æ¯«å…‹ | å‡æ™¶æ³¨å°„åŠ‘ | ç„¡æ³•åˆ‡é™¤æˆ–è½‰ç§»æ€§è„‚è‚ªè‚‰ç˜¤æˆ–å¹³æ»‘è‚Œè‚‰ç˜¤ |

## ç´°èƒæ¯’æ€§

| é …ç›® | å…§å®¹ |
|------|------|
| ç´°èƒæ¯’æ€§åˆ†é¡ | æŠ—è…«ç˜¤æŠ—ç”Ÿç´  (æµ·æ´‹ä¾†æº) |
| éª¨é«“æŠ‘åˆ¶é¢¨éšª | é«˜åº¦ |
| è‡´åæ€§åˆ†ç´š | ä¸­åº¦è‡³é«˜åº¦ |
| ç›£æ¸¬é …ç›® | CBCï¼ˆå«åˆ†é¡ï¼‰ã€è‚è…åŠŸèƒ½ã€CK |
| è™•ç½®é˜²è­· | éœ€ä¾ç´°èƒæ¯’æ€§è—¥ç‰©è™•ç½®è¦ç¯„æ“ä½œ |
| ç‰¹æ®Šæ³¨æ„ | å¯èƒ½å¼•èµ·æ©«ç´‹è‚Œæº¶è§£ç—‡ï¼Œéœ€ç›£æ¸¬è‚Œé…¸æ¿€é…¶ |

## å®‰å…¨æ€§è€ƒé‡

- **è‚æ¯’æ€§**ï¼šéœ€å®šæœŸç›£æ¸¬è‚åŠŸèƒ½
- **éª¨é«“æŠ‘åˆ¶**ï¼šå¯èƒ½å°è‡´å—œä¸­æ€§ç™½è¡€çƒæ¸›å°‘ã€è¡€å°æ¿æ¸›å°‘
- **æ©«ç´‹è‚Œæº¶è§£ç—‡**ï¼šç½•è¦‹ä½†åš´é‡çš„ä¸è‰¯åæ‡‰
- **å¿ƒè‡Ÿæ¯’æ€§**ï¼šéœ€ç›£æ¸¬ QT é–“éš”

### è—¥ç‰©-é£Ÿç‰©äº¤äº’ä½œç”¨ (DFI)

<div class="dfi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**è‘¡è„æŸšæ± (grapefruit juice)** ğŸŸ¡ Moderate
- å½±éŸ¿ï¼šCoadministration with grapefruit juice may increase the plasma concentrations of trabectedin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by cert...
- å»ºè­°ï¼šConsumption of grapefruit or grapefruit juice during treatment with trabectedin should be avoided.  Excessive use of alcohol is also not recommended.  Patients should be advised to seek medical attent...


### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a>ï¼ˆåŸæ–‡å…§å®¹è«‹åƒé–±è©²ç¶²ç«™ï¼‰</div>

**Cardiomyopathies** ğŸŸ¡ Moderate
- è«‹åƒé–± DDInter 2.0 äº†è§£è©³æƒ…ã€‚

**è‚è‡Ÿç–¾ç—…** ğŸŸ¡ Moderate
- éœ€å¯†åˆ‡ç›£æ¸¬ï¼›æœ‰è‚æ¯’æ€§é¢¨éšªã€‚

**Sepsis** ğŸŸ¡ Moderate
- éœ€å¯†åˆ‡ç›£æ¸¬ï¼›å¯èƒ½æœ‰è‡´å‘½é¢¨éšªã€‚

**Rhabdomyolysis** ğŸŸ¡ Moderate
- è«‹åƒé–± DDInter 2.0 äº†è§£è©³æƒ…ã€‚

**Kidney Failure, Chronic** ğŸŸ¡ Moderate
- å¯èƒ½éœ€èª¿æ•´åŠ‘é‡ã€‚

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

**æ±ºç­–ï¼šProceed with Guardrails**

**ç†ç”±ï¼š**
Trabectedin åœ¨ä¹³è…ºç™Œä¸­çš„å¤šé …è‡¨åºŠè©¦é©—åŠæ–‡ç»é¡¯ç¤ºå…¶æ½›åœ¨ç™‚æ•ˆï¼Œç‰¹åˆ¥æ˜¯å° BRCA çªè®Šæ‚£è€…ã€‚å…¶ç¨ç‰¹çš„ä½œç”¨æ©Ÿè½‰èˆ‡ç¾æœ‰ä¹³è…ºç™Œæ²»ç™‚è—¥ç‰©ä¸åŒï¼Œå¯èƒ½æä¾›æ–°çš„æ²»ç™‚é¸æ“‡ã€‚

**è‹¥è¦æ¨é€²éœ€è¦ï¼š**
- é‡å°ä¹³è…ºç™Œçš„å¤§å‹éš¨æ©Ÿå°ç…§è©¦é©—
- BRCA çªè®Šç‹€æ…‹çš„ç”Ÿç‰©æ¨™è¨˜ç¯©é¸ç­–ç•¥
- èˆ‡ç¾æœ‰ä¹³è…ºç™Œæ²»ç™‚æ–¹æ¡ˆçš„æ¯”è¼ƒç ”ç©¶

---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Inclisiran]({{ "/drugs/inclisiran/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Zanubrutinib]({{ "/drugs/zanubrutinib/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Scopolamine]({{ "/drugs/scopolamine/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Brivaracetam]({{ "/drugs/brivaracetam/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Polymyxin B]({{ "/drugs/polymyxin_b/" | relative_url }}) - è­‰æ“šç­‰ç´š L5

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Trabectedinè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/trabectedin/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_trabectedin,
  title = {Trabectedinè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/trabectedin/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
